NCT05361382 · Phase 1 · ACTIVE NOT RECRUITING
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
This trial is comparing two different PET scan tracers — Flortaucipir and MK-6240 — that are used to measure tau tangles in the brain, a hallmark of Alzheimer's. The goal is to figure out how well the two tracers agree with each other so researchers can combine or compare data from studies that used different tracers. This is a Phase 1 imaging study, meaning it is focused on measurement and safety, not on testing a treatment.
You may qualify if
- Have a study partner who will be able to provide an independent evaluation of functioning.
- Willing and capable of undergoing repeated MR/PET imaging.
- Fluent in a language approved by the coordinating center.
- At screening, must have no cognitive impairment, or meet criteria for single- or multiple-domain amnestic mild cognitive impairment or Alzheimer's disease dementia.
You're excluded if
- Inability to provide informed consent by self or by proxy.
- Pregnant or breastfeeding women.
- Have any condition or are taking any medication that could increase the risk to the participant, limit the ability to tolerate or interfere with the results of the tests and procedures (in the opinion of the investigator).
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-10-29